Physician profile
Clarke Latimer
NPI 1700041290
$2,444.29
in general payments reported to CMS, 2019-2025
24 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.25 · 2020: $52.87 · 2022: $197 · 2023: $940 · 2024: $689 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $444.78 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $342.98 | 2019-2025 | |
| Exact Sciences Corporation | $203.84 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $190.08 | 2022-2024 | Mounjaro |
| Abbvie INC. | $189.12 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $164.01 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Abbott Laboratories | $128.70 | 2019-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $127.23 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $87.48 | 2022-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.04 | 2023-2025 | Synjardy, Jardiance |
| Amgen INC. | $66.03 | 2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $60.71 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $56.55 | 2025 | |
| Sanofi Pasteur INC. | $47.81 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.73 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $39.95 | 2020 | |
| Hologic Sales and Service, LLC | $38.22 | 2023-2024 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.87 | 2023-2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $21.51 | 2025 | Keveyis |
| Actelion Pharmaceuticals US, INC. | $20.75 | 2024 | Opsumit, Uptravi |
| Astellas Pharma US INC | $18.22 | 2024 | Veozah |
| Ibsa Pharma INC. | $18.06 | 2024 | Tirosint, Licart |
| Astrazeneca Pharmaceuticals Lp | $15.25 | 2024 | Airsupra |
| Bavarian Nordic A/S | $14.37 | 2025 | Vivotif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarke Latimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.